Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
Kura Oncology (KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced it will release its Q4 and full year 2024 financial results after U.S. market close on Wednesday, February 26, 2025.
The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss financial results and provide a corporate update. Investors can access the live call via phone using the numbers (800) 579-2543 (domestic) or (785) 424-1789 (international) with conference ID: KURAQ4. A live webcast and replay will be available on the company's investor relations website.
Kura Oncology (KURA), un'azienda biofarmaceutica in fase clinica focalizzata su medicinali di precisione per il trattamento del cancro, ha annunciato che rilascerà i risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato statunitense il mercoledì 26 febbraio 2025.
L'azienda ospiterà un webcast e una conferenza telefonica alle 16:30 ET / 13:30 PT nello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento aziendale. Gli investitori possono accedere alla chiamata in diretta tramite telefono utilizzando i numeri (800) 579-2543 (nazionale) o (785) 424-1789 (internazionale) con ID conferenza: KURAQ4. Un webcast dal vivo e una registrazione saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda.
Kura Oncology (KURA), una empresa biofarmacéutica en etapa clínica centrada en medicamentos de precisión para el tratamiento del cáncer, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado estadounidense el miércoles 26 de febrero de 2025.
La empresa realizará un webcast y una llamada de conferencia a las 4:30 p.m. ET / 1:30 p.m. PT el mismo día para discutir los resultados financieros y proporcionar una actualización corporativa. Los inversores pueden acceder a la llamada en vivo por teléfono utilizando los números (800) 579-2543 (nacional) o (785) 424-1789 (internacional) con el ID de conferencia: KURAQ4. Un webcast en vivo y una repetición estarán disponibles en el sitio web de relaciones con inversores de la empresa.
Kura Oncology (KURA)는 암 치료를 위한 정밀 의약품에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 2월 26일 수요일에 미국 시장 마감 후 2024년 4분기 및 연간 재무 결과를 발표할 것이라고 발표했습니다.
회사는 같은 날 오후 4시 30분 ET / 오후 1시 30분 PT에 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 웹캐스트 및 컨퍼런스 콜을 주최합니다. 투자자는 전화로 (800) 579-2543 (국내) 또는 (785) 424-1789 (국제) 번호를 사용하여 라이브 전화를 이용할 수 있으며, 회의 ID는 KURAQ4입니다. 회사의 투자자 관계 웹사이트에서 라이브 웹캐스트 및 재생이 제공될 예정입니다.
Kura Oncology (KURA), une entreprise biopharmaceutique en phase clinique axée sur les médicaments de précision pour le traitement du cancer, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 après la clôture du marché américain le mercredi 26 février 2025.
L'entreprise organisera un webcast et une conférence téléphonique à 16h30 ET / 13h30 PT le même jour pour discuter des résultats financiers et fournir une mise à jour de l'entreprise. Les investisseurs peuvent accéder à l'appel en direct par téléphone en utilisant les numéros (800) 579-2543 (national) ou (785) 424-1789 (international) avec l'ID de conférence : KURAQ4. Un webcast en direct et une rediffusion seront disponibles sur le site Web des relations avec les investisseurs de l'entreprise.
Kura Oncology (KURA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzise Medikamente zur Krebsbehandlung konzentriert, hat angekündigt, dass es seine Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 nach dem US-Marktschluss am Mittwoch, den 26. Februar 2025, veröffentlichen wird.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET / 13:30 Uhr PT ein Webcast und eine Telefonkonferenz veranstalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über die Nummern (800) 579-2543 (national) oder (785) 424-1789 (international) mit der Konferenz-ID: KURAQ4 auf den Live-Anruf zugreifen. Ein Live-Webcast und eine Aufzeichnung werden auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2024 financial results after the close of U.S. financial markets on Wednesday, February 26, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ4. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (the “FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Patti Bank
Managing Director
(415) 513-1284
patti.bank@icrhealthcare.com
Media:
Alexandra Weingarten
Associate Director, Corporate Communications
& Investor Relations
(858) 500-8822
alexandra@kuraoncology.com
FAQ
When will Kura Oncology (KURA) release its Q4 and full year 2024 earnings?
How can investors join Kura Oncology's (KURA) Q4 2024 earnings call?
What time is Kura Oncology's (KURA) Q4 2024 earnings call?
Where can I access the replay of Kura Oncology's (KURA) Q4 2024 earnings call?
